The natural history of prostate cancer represents an intriguing variation of the multistep process of carcinogenesis. It is clearly established that life-threatening prostate cancer results from low- frequency progression of the common, often microscopic, but clinically insignificant latent form of the disease and not the inexorable growth associated with most small malignancies. Interestingly, both genetic and environmental factors appear to be associated with this rate limiting step. We have observed genetic differences in the susceptibility to ras+myc- induced carcinogenesis using the mouse prostate reconstitution (MPR) model. Our genetic studies using sensitive C57BL/6 mice and the resistant Balb/c mice are consistent with polygenic determinants for carcinogenesis which include a dominant growth suppressor. We have identified a distinct pattern of cAMP mediated gene expression that correlates with sensitivity to ras+myx-induced carcinogenesis in four inbred strains of mice. Marked differences in the prostate specific level of induction by forskolin for c-fos and jun-B were observed in resistant Balb/c and A/J mice but not sensitive C57BL/6 and DBA/2 mice. Chronic exposure to pharmacological levels of testosterone dramatically increased the incidence of ras+myc-induced carcinomas in resistant Balb/c mice and appears to suppress levels of jun-B mRNA. In a large panel of cell lines derived from ras+myc-induced C57BL/6 carcinomas, we have demonstrated a second novel mechanism through which tumor suppressor activity may be eliminated. In 6 out of 7 tumor cell lines, stabilization of wild-type p53 protein was observed indicating this biological feature was highly selected for during progression. We will continue to focus on genetically programmed resistance/susceptibility to ras+myc-induced carcinogenesis using the MPR system. Functional criteria for evaluating a role in carcinogenesis for the observed cAMP-mediated hypersensitive pattern of induction for specific AP-1 complex genes will be established and additional regulators of AP-1 activity including phorbol esters in ras+myc- sensitive and resistant mice will be evaluated. The genes responsible for prostate specific AP-1 induction will be mapped together with the tumorigenic response to ras+myc using recombinant inbred mice. We will further test a role for jun-B as a tumor suppressor gen in ras+myc- resistant Balb/c mice by firmly establishing its regulation by testosterone and directly linking its expression with reduced tumorigenicity in gene transfer studies. We will investigate the mechanism of stabilization of wild type p53 protein in established cell lines and determine its biological significance by comparing similarly derived cell lines which demonstrate this activity to those that do not. Finally, we will extend and explore an observed suppression of ras+myc- induced carcinogenesis by specific retinoids and examine possible relationships to our candidate tumor suppressor gene activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA050588-04
Application #
3195151
Study Section
Chemical Pathology Study Section (CPA)
Project Start
1989-09-08
Project End
1996-07-31
Budget Start
1992-09-08
Budget End
1993-07-31
Support Year
4
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
Schools of Medicine
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Fujita, Tetsuo; Satoh, Takefumi; Timme, Terry L et al. (2014) Combined therapeutic effects of adenoviral vector-mediated GLIPR1 gene therapy and radiotherapy in prostate and bladder cancer models. Urol Oncol 32:92-100
Li, Likun; Yang, Guang; Ren, Chengzhen et al. (2013) Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2. Mol Oncol 7:484-96
Yang, Guang; Goltsov, Alexei A; Ren, Chengzhen et al. (2012) Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer. Mol Cancer Res 10:218-29
Floryk, Daniel; Kurosaka, Shinji; Tanimoto, Ryuta et al. (2011) Castration-induced changes in mouse epididymal white adipose tissue. Mol Cell Endocrinol 345:58-67
Tabata, K; Kurosaka, S; Watanabe, M et al. (2011) Tumor growth and metastasis suppression by Glipr1 gene-modified macrophages in a metastatic prostate cancer model. Gene Ther 18:969-78
Li, Likun; Ren, Chengzhen; Yang, Guang et al. (2011) GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction. Cancer Res 71:7694-704
Thompson, Timothy C (2010) Glioma pathogenesis-related protein 1: tumor-suppressor activities and therapeutic potential. Yonsei Med J 51:479-83
Langeberg, Wendy J; Tahir, Salahaldin A; Feng, Ziding et al. (2010) Association of caveolin-1 and -2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes. Prostate 70:1020-35
Floryk, Daniel; Thompson, Timothy C (2008) Perifosine induces differentiation and cell death in prostate cancer cells. Cancer Lett 266:216-26
Tahir, Salahaldin A; Ren, Chengzhen; Timme, Terry L et al. (2003) Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. Clin Cancer Res 9:3653-9

Showing the most recent 10 out of 65 publications